Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Hans-Jürgen Stellbrink; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G Sprenger; John D. C. Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce; ASSERT Study Group

doi:10.1086/656417

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Hans-Jürgen Stellbrink
, Chloe Orkin
, Jose Ramon Arribas
, Juliet Compston
, Jan Gerstoft
, Eric Van Wijngaerden
, Adriano Lazzarin
, Giuliano Rizzardini
, Herman G Sprenger
, John D. C. Lambert
, Gunta Sture
, David Leather
, Sara Hughes
, Patrizia Zucchi
, Helen Pearce
, ASSERT Study Group

379 Citations (Scopus)

Abstract

Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.

Original language	English
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	51
Issue number	8
Pages (from-to)	963-72
Number of pages	10
DOIs	https://doi.org/10.1086/656417
Publication status	Published - 15 Oct 2010

Access to Document

10.1086/656417

Cite this

Stellbrink, H.-J., Orkin, C., Arribas, J. R., Compston, J., Gerstoft, J., Van Wijngaerden, E., Lazzarin, A., Rizzardini, G., Sprenger, H. G., Lambert, J. D. C., Sture, G., Leather, D., Hughes, S., Zucchi, P., Pearce, H., & ASSERT Study Group (2010). Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51(8), 963-72. https://doi.org/10.1086/656417

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. / Stellbrink, Hans-Jürgen; Orkin, Chloe; Arribas, Jose Ramon et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 51, No. 8, 15.10.2010, p. 963-72.

Research output: Contribution to journal › Journal article › Research › peer-review

Stellbrink, H-J, Orkin, C, Arribas, JR, Compston, J, Gerstoft, J, Van Wijngaerden, E, Lazzarin, A, Rizzardini, G, Sprenger, HG, Lambert, JDC, Sture, G, Leather, D, Hughes, S, Zucchi, P, Pearce, H & ASSERT Study Group 2010, 'Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 51, no. 8, pp. 963-72. https://doi.org/10.1086/656417

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 Oct 15;51(8):963-72. doi: 10.1086/656417

Stellbrink, Hans-Jürgen ; Orkin, Chloe ; Arribas, Jose Ramon et al. / Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 ; Vol. 51, No. 8. pp. 963-72.

@article{00db3d14baee4fe0af02dc84970b059d,

title = "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",

abstract = "Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.",

author = "Hans-J{\"u}rgen Stellbrink and Chloe Orkin and Arribas, \{Jose Ramon\} and Juliet Compston and Jan Gerstoft and \{Van Wijngaerden\}, Eric and Adriano Lazzarin and Giuliano Rizzardini and Sprenger, \{Herman G\} and Lambert, \{John D. C.\} and Gunta Sture and David Leather and Sara Hughes and Patrizia Zucchi and Helen Pearce and \{ASSERT Study Group\}",

year = "2010",

month = oct,

day = "15",

doi = "10.1086/656417",

language = "English",

volume = "51",

pages = "963--72",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1537-6591",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

AU - Stellbrink, Hans-Jürgen

AU - Orkin, Chloe

AU - Arribas, Jose Ramon

AU - Compston, Juliet

AU - Gerstoft, Jan

AU - Van Wijngaerden, Eric

AU - Lazzarin, Adriano

AU - Rizzardini, Giuliano

AU - Sprenger, Herman G

AU - Lambert, John D. C.

AU - Sture, Gunta

AU - Leather, David

AU - Hughes, Sara

AU - Zucchi, Patrizia

AU - Pearce, Helen

AU - ASSERT Study Group

PY - 2010/10/15

Y1 - 2010/10/15

N2 - Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.

AB - Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.

U2 - 10.1086/656417

DO - 10.1086/656417

M3 - Journal article

C2 - 20828304

SN - 1537-6591

VL - 51

SP - 963

EP - 972

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 8

ER -

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Abstract

Access to Document

Fingerprint

Cite this